Skip to main content

Publisher: Wiley-Blackwell

Volume 29, Supplement 3, July 1999

Experimental models in asthma
pp. 82-86(5)
Author: Holgate

Favourites:
ADD

Assessment of antihistamine efficacy and potency
pp. 87-97(11)
Author: Howarth

Favourites:
ADD

Experimental models of skin inflammation
pp. 105-108(4)
Author: Clough

Favourites:
ADD

Assessment of urticaria and angio-oedema
pp. 109-112(4)
Author: Friedmann

Favourites:
ADD
Favourites:
ADD
Favourites:
ADD

CNS effects of histamine H1 antagonists
pp. 143-146(4)
Authors: Rihoux; Donnelly

Favourites:
ADD
Favourites:
ADD
Favourites:
ADD

The systemic safety of fexofenadine HCl
pp. 163-170(8)
Authors: Mason; Reynolds; Rao

Favourites:
ADD
Favourites:
ADD

Cardiac ion channels and antihistamines: possible mechanisms of cardiotoxicity
pp. 182-189(8)
Authors: Taglialatela; Castaldo; Pannaccione; Giorgio; Genovese; Marone; Annunziato

Favourites:
ADD
Favourites:
ADD

Cardiovascular profile of loratadine
pp. 197-199(3)
Authors: Hey; Affrime; Cobert; Kreutner; Cuss

Favourites:
ADD

A review of the cardiac systemic side-effects of antihistamines: ebastine
pp. 200-205(6)
Authors: Moss; Chaikin; Garcia; Gillen; Roberts; Morganroth

Favourites:
ADD

QT interval monitoring during clinical studies with mizolastine, a new H1 antihistamine
pp. 206-211(6)
Authors: Delauche-Cavallier; Chaufour; Guérault; Lacroux; Murrieta; Wajman

Favourites:
ADD

Cardiovascular safety of fexofenadine HCl
pp. 212-216(5)
Authors: Pratt; Brown; Rampe; Mason; Russell; Reynolds; Ahlbrandt

Favourites:
ADD
Favourites:
ADD

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more